Moderna's Bigger Catalyst: Full FDA Approval or Booster Authorization?
Moderna (NASDAQ: MRNA) awaits two decisions from the U.S. Food and Drug Administration. The company hopes to win full approval for its COVID-19 vaccine. It also wants the FDA to give a green light for a booster dose of its vaccine. In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss which of these two pending FDA decisions could provide the bigger catalyst for Moderna.
Source Fool.com
